FineHeart, a preclinical medical device company that has developed an implantable cardiac output management system designed to address the unmet need of patients suffering from severe heart failure, announced the successful completion of a €15 million funding round. This enables FineHeart to prepare for First-In-Human clinical trials planned for 2022.

Written by

WITH US, YOU CANCO-INVEST IN DEEP TECH STARTUPS

Verve's investor network

With annual investments of EUR 60-70 mio, we belong to the top 10% most active startup investors in Europe. We therefore get you into competitive financing rounds alongside other world-class venture capital funds.

We empower you to build your individual portfolio.

Sign up to receive our regular newsletter and learn about investing in technologies that are changing the world.

Privacy Preference Center